Nektar Therapeutics Income Tax Examination, Penalties and Interest Expense
Nektar Therapeutics (NKTR) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-01.
Discontinued › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2013-03-01
- Nektar Therapeutics income tax examination, penalties and interest expense for fiscal 2012 was $0.00.
- Nektar Therapeutics income tax examination, penalties and interest expense for fiscal 2011 was $0.00.
- Nektar Therapeutics income tax examination, penalties and interest expense for fiscal 2010 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|
| 2012-12-31 | $0.00 10-K · filed 2013-03-01 |
| 2011-12-31 | $0.00 10-K · filed 2013-03-01 |
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |